During Tuesday’s current trade, Cincinnati Bell Inc. (NYSE:CBB)’s shares incline 0.24% to $4.10.
Cincinnati Bell Inc. (CBB) declared that its partner plans to enter into a purchase agreement with CyrusOne Inc. (“CyrusOne”) to sell 4,300,000 operating partnership units (plus up to an additional 1,695,000 operating partnership units if the underwriters exercise their option described below) in CyrusOne’s operating partnership, CyrusOne LP. CyrusOne declared recently it had commenced the public offering of 11,300,000 shares of its common stock and granted the underwriters an option to purchase up to 1,695,000 additional shares, a portion of the net proceeds of which will be used to acquire operating partnership units from a partner of Cincinnati Bell.
Upon completion of the acquisition and of CyrusOne LP’s issuance of operating partnership units to CyrusOne in exchange for the remaining net proceeds from CyrusOne’s public offering, Cincinnati Bell anticipates to effectively own about 13.7% (or about 11.3% if the underwriters in CyrusOne’s public offering exercise their option to purchase additional shares of CyrusOne’s common stock in full, the net proceeds of which would be used to purchase additional operating partnership units from a partner of Cincinnati Bell) of CyrusOne through its interests in the outstanding shares of common stock of CyrusOne and its interests in the common units of limited partnership interest of CyrusOne LP, which are exchangeable into shares of common stock of CyrusOne.
Advaxis, Inc. (NASDAQ:ADXS)‘s shares drop -2.59% to $20.33, during the current trading session Tuesday’s, hitting its highest level.
Advaxis, Inc. (ADXS) declared the company will be added to the Russell Global and Russell 3000® Indexes. This inclusion will become effective upon the close of trading on June 26, when the Russell Investment Group reconstitutes its comprehensive set of U.S. and global indexes, according to a preliminary list of additions posted on June 12.
Advaxis, Inc., a clinical stage biotechnology company, focuses on the discovery, development, and commercialization of Lm-LLO cancer immunotherapies in the United States. The Lm-LLO immunotherapy platform technology stimulates the immune system to induce antigen-specific anti-tumor immune responses involving innate and adaptive arms of the immune system by inhibiting the T-cells, tregs, and myeloid-derived suppressor cells, and MDSC to promote immunologic tolerance of cancer cells in the tumor. Its lead product ADXS-HPV, an Lm-LLO immunotherapy product candidate used for the treatment of human papilloma virus (HPV) associated cancers, accomplished its Phase II study.
In an afternoon trade, Infosys Ltd ADR (NYSE:INFY)‘s shares plunge -0.52% to $32.36.
Infosys Ltd ADR (INFY) a global leader in consulting, technology, outsourcing and next-generation services, declared that it has accomplished the implementation of its Smart Oilfield Services Solution for SAP ERP at FTS International (FTSI), the largest private well completion company in North America , allowing the company to achieve a noteworthy milestone in its planned business transformation.
FTSI has grown rapidly since its inception. The company’s IT infrastructure, based on a series of legacy systems, required an overhaul to manage that growth and avoid keeping the company’s operations in silos. Within 14 months, Infosys assisted FTSI implement 15 SAP modules across 20 locations for over 1,400 users, thus enabling the company to improve its operating metrics and to leverage an upgraded IT platform for future growth.
Infosys Limited, together with its auxiliaries, provides business consulting, technology, engineering, and outsourcing services in North America, Europe, India, and internationally. Its solutions comprise business information technology (IT) services comprising application development and maintenance, independent validation services, infrastructure administration, business process administration, and engineering services comprising of product engineering and life cycle solutions; and consulting and systems integration services, counting consulting, enterprise solutions, systems integration, and advanced technologies.
FedEx Corporation (NYSE:FDX), during its Tuesday’s current trading session -0.16% loss and closed at $176.01.
FedEx Corporation (FDX) stated adjusted earnings of $2.66 per diluted share for the fourth quarter ended May 31, contrast to adjusted earnings of $2.54 per diluted share a year ago. For fiscal 2015, adjusted earnings were $8.95 per diluted share, contrast to $7.05 per diluted share a year ago. Without adjustments, FedEx stated a loss of $3.16 per diluted share for the fourth quarter contrast to a profit of $2.62 per diluted share a year ago, and earnings of $3.65 per diluted share for the full fiscal year, contrast to $7.48 per diluted share last year.
Quarterly merged earnings have been adjusted for formerly declared changes in pension accounting ($4.88 per diluted share), aircraft impairments ($0.62 per diluted share), a legal reserve enhance ($0.47 per diluted share) and changes in segment reporting (favorable $0.15 per diluted share).
FedEx Corporation provides transportation, e-commerce, and business services in the United States and internationally. The company’s FedEx Express segment provides various shipping services for the delivery of packages and freight; international trade services specializing in customs brokerage, and ocean and air freight forwarding services; international trade advisory services, such as assistance with the customs-trade partnership against terrorism program; and customs clearance services, in addition to global trade data, an information tool that allows customers to track and manage imports.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
